NEWS
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024
HOOKIPA Pharma (NASDAQ: HOOK) announced that updated Phase 2 data for eseba-vec (HB200) plus pembrolizumab in first-line recurrent/metastatic HPV16-positive head and neck cancer will be presented at SITC 2024. The presentation will be delivered as a late-breaking poster by Dr. Alan Ho, Chief of Head and Neck Oncology Service at Memorial Sloan Cancer Center, on November 9, 2024, in Houston, Texas.
The presentation will focus on updated results in PD-L1 CPS ≥20 patients receiving the combination treatment. The poster will be accessible on HOOKIPA's website under the Scientific Publications section.
HOOKIPA Pharma (NASDAQ: HOOK) announced that updated Phase 2 data for eseba-vec (HB200) plus pembrolizumab in first-line recurrent/metastatic HPV16-positive head and neck cancer will be presented at SITC 2024. The presentation will be delivered as a late-breaking poster by Dr. Alan Ho, Chief of Head and Neck Oncology Service at Memorial Sloan Cancer Center, on November 9, 2024, in Houston, Texas.
The presentation will focus on updated results in PD-L1 CPS ≥20 patients receiving the combination treatment. The poster will be accessible on HOOKIPA's website under the Scientific Publications section.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2538Followers
107Following
28KVisitors
Follow